IL17A and myeloid sarcoma: This intervention positively influenced several MS-related aspects, including gut microbiota, relapse rate, and inflammatory markers, reporting a decrease in IL-17-producing CD4+ T lymphocytes, increased abundance of the Lachnospiraceae family, and reduced relapse rate in the high-vegetable/low-protein group [53].